TELO

Telomir Pharmaceuticals Inc

1.01

Oct 20 • 3:59 PM ET -0.03 (-2.88%)

1.03

Aftermarket • 7:30 PM ET +0.02 (1.98%)

Healthcare Biotechnology USA Micro NASD

Peers: ANVS ATOS BIVI CLNN GANX ALZN JUNS LGVN NRSN ENVB

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	74.35M
Enterprise Value	69.32M
Income	-51.99M
Sales	0.00M
Book/sh	0.07
Cash/sh	0.07
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	2
IPO	Feb 09, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	13.80
P/C	14.38
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	16.14
Current Ratio	16.14
Debt/Eq	0.03
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.91
EPS next Y	-0.11
EPS next Q	-0.03
EPS this Y	-
EPS next Y	-
EPS next 5Y	32.79%
EPS past 3/5Y	-125.22% -189.25%
Sales past 3/5Y	- -
EPS Y/Y TTM	-67.73%
Sales Y/Y TTM	-
EPS Q/Q	-365.54%
Sales Q/Q	-
Earnings	Sep 02
EPS/Sales Surpr.	- -

Insider Own	0.00%
Insider Trans	-
Inst Own	4.01%
Inst Trans	5.73%
ROA	-189.68%
ROE	-213.10%
ROIC	-116.74%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-11.29%
SMA50	-11.87%
SMA200	-18.50%
Trades

Shs Outstand	73.62M
Shs Float	73.62M
Short Float	1.12%
Short Ratio	8.66
Short Interest	0.83M
52W High	1.70 -40.59%
52W Low	0.89 13.68%
Volatility	6.72% 6.94%
ATR (14)	0.08
RSI (14)	31.44
Beta	-0.28
Rel Volume	0.83
Avg Volume	95.39K
Volume	78,961

Perf Week	-7.34%
Perf Month	-18.55%
Perf Quarter	-4.72%
Perf Half Y	-27.34%
Perf YTD	-24.06%
Perf Year	-39.16%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	6.00
Prev Close	1.04
Price	1.01
Change %	-2.88%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-21-25	Initiated	Rodman & Renshaw	Buy	$15

Oct-06-26 08:00AM	Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company (GlobeNewswire)
Sep-17-26 08:30AM	Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD) (GlobeNewswire)
Sep-14-26 08:00AM	Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models (GlobeNewswire)
Aug-10-26 08:00AM	Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models (GlobeNewswire)
Jun-15-26 08:00AM	Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model (ACCESSWIRE)
08:00AM	Loading…
May-20-26 08:00AM	Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease (ACCESSWIRE) +7.38%
Apr-30-26 08:00AM	Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer (ACCESSWIRE)
Apr-24-26 09:00AM	Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) (ACCESSWIRE)
Apr-14-26 07:00AM	Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma (TMX Newsfile)
Mar-31-26 08:00AM	Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer (ACCESSWIRE) +14.04%
07:00AM	Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman (TMX Newsfile)
Feb-17-26 08:00AM	Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models (ACCESSWIRE) +5.50%
Feb-05-26 08:00AM	Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging (ACCESSWIRE)
Jan-05-26 08:00AM	Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models (ACCESSWIRE) +11.19%
Dec-18-25 07:30AM	Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development (ACCESSWIRE)
08:00AM	Loading…
Nov-25-25 08:00AM	Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells (ACCESSWIRE)
Nov-21-25 07:30AM	Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells (ACCESSWIRE) -7.91%
Nov-12-25 08:00AM	Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line (ACCESSWIRE)
Oct-23-25 07:30AM	Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's "Kill-and-Clean" Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo (ACCESSWIRE) +7.25%
Oct-21-25 07:30AM	Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth (ACCESSWIRE) -9.64%
Oct-14-25 08:00AM	Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer (ACCESSWIRE)
Oct-09-25 07:30AM	Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells (ACCESSWIRE) +16.97%
Oct-07-25 07:30AM	Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance (ACCESSWIRE) +26.76%
Sep-18-25 08:00AM	Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies (ACCESSWIRE) +5.26%
Sep-09-25 08:00AM	Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy (ACCESSWIRE) +10.57%
Aug-28-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:00AM	Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases (ACCESSWIRE)
Aug-07-25 08:00AM	Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction (ACCESSWIRE) -9.24%
Jul-24-25 08:00AM	Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's (ACCESSWIRE) +11.17%
Jul-18-25 10:32AM	BC-Most Active Stocks (Associated Press Finance) +88.43%
08:00AM	Loading…
08:00AM	Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin (ACCESSWIRE)
Jun-18-25 09:15AM	Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging (ACCESSWIRE) -5.38%
09:00AM	EXCLUSIVE: Telomir Pharmaceuticals Says Preclinical Drug Candidate Prevents Premature Aging In Patient-Derived Cells From Children With Progeria (Benzinga)
Jun-13-25 01:58PM	TELO Rises on Promising Telomir-1 Preclinical Results (Insider Monkey)
Jun-11-25 09:30AM	Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model (ACCESSWIRE)
Jun-05-25 08:30AM	Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome (ACCESSWIRE)
07:41AM	EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder (Benzinga)
Jun-02-25 08:30AM	Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform (ACCESSWIRE) +7.97%
May-29-25 08:30AM	Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints (ACCESSWIRE)
May-21-25 09:00AM	Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND (ACCESSWIRE) -6.99%
08:15AM	EXCLUSIVE: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND (Benzinga)
May-15-25 08:00AM	Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity (ACCESSWIRE) -11.28%
May-07-25 08:00AM	Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia (ACCESSWIRE)
Mar-19-25 08:00AM	Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells (ACCESSWIRE) +5.58%
Feb-26-25 08:00AM	Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines (ACCESSWIRE)
Feb-21-25 08:00AM	Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market (ACCESSWIRE) -6.46%
Feb-20-25 04:01PM	Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration (Benzinga)
Feb-18-25 08:00AM	Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD) (ACCESSWIRE) -8.62%
Jan-28-25 08:00AM	Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses (ACCESSWIRE)
Jan-07-25 08:00AM	Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging) (ACCESSWIRE) +7.57%
Dec-23-24 07:30AM	Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease (ACCESSWIRE) -10.04%
06:46AM	EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease (Benzinga)
Dec-12-24 08:30AM	Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price (ACCESSWIRE)
Dec-03-24 07:30AM	Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1 (ACCESS Newswire) +14.82%
Nov-21-24 07:00AM	Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1 (ACCESSWIRE) +6.43%
Sep-26-24 04:00PM	Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday (ACCESSWIRE) +5.57%
Sep-04-24 07:30AM	Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications (ACCESSWIRE)
Aug-20-24 07:30AM	Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs (ACCESSWIRE) -13.61%
Aug-12-24 08:30AM	Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman (GlobeNewswire) +15.62%
Jul-02-24 08:30AM	Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes (GlobeNewswire)
Jun-17-24 04:10PM	Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel (GlobeNewswire)
May-30-24 08:30AM	Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1 (GlobeNewswire) -7.62%
May-24-24 09:30AM	New to The Street TV Announces Episode 575 with its Four Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Saturday, May 25, 2024, at 6:30 PM ET (GlobeNewswire) +6.98%
May-16-24 09:30AM	Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support (GlobeNewswire)
May-13-24 10:53PM	TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace) -5.33%
May-07-24 03:02PM	Telomir Pharmaceuticals sees breakthrough potential in Anti-Aging Treatment with Telomir 1 (News Direct)
Apr-16-24 08:30AM	Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C. (GlobeNewswire) -5.32%
Apr-02-24 08:30AM	Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024 (GlobeNewswire)
Mar-29-24 04:44PM	UPDATE Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines (GlobeNewswire)
Mar-26-24 08:30AM	Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines (GlobeNewswire)
Mar-22-24 08:30AM	Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th (GlobeNewswire)
Mar-14-24 08:30AM	Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Science (GlobeNewswire) -9.83%
Mar-07-24 08:30AM	Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference (GlobeNewswire)
Mar-05-24 08:30AM	Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal (GlobeNewswire)
Feb-13-24 04:05PM	Telomir Pharmaceuticals Announces Closing of Initial Public Offering (GlobeNewswire) +12.16% +69.76%

Show Previous News

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm's initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL.

Chairman of the Board & CEOMr. Erez Aminov

Chief Financial OfficerMr. Andriy Mushak CPA

Chief Scientific AdvisorDr. Itzchak Angel Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TELO

Telomir Pharmaceuticals Inc

Upgrade your Finviz experience